Why Are Top Stocks Moving Before the Bell Today? Pre-Market Movers July 29, 2026

Wednesday, July 29, 2026 — The pre-market session is already white-hot this morning. As of 7:45 AM ET, five major stocks are ripping higher on earnings beats, FDA approvals, and strong guidance updates. NVIDIA (NVDA) is up 8.2% in pre-market trading to $147.35 on 12.4M shares (versus its 30-day average of 2.1M), driven by stronger-than-expected Q3 data center revenue guidance. Tesla (TSLA) surged 6.1% to $248.90 after reporting surprise June delivery numbers. Moderna (MRNA) is the biggest pre-market gainer, up 14.7% to $89.23 on positive Phase 3 vaccine trial data. If you're asking "why is the stock market surging pre-market today," these three names — plus moves in AMD and Eli Lilly — are the reason. The question now: will these gains hold through the open, or will profit-taking erase the overnight rally?

What's Driving the Pre-Market Surge Wednesday?

The catalyst list this morning is unusually dense. NVIDIA's 8.2% jump is anchored on leaked internal guidance suggesting Q3 data center revenue will hit $23.8B — a $1.2B beat over consensus expectations. This marks the third consecutive quarter of accelerating AI chip demand, signaling that the infrastructure buildout for large language models is moving faster than Wall Street anticipated. The company will confirm (or walk back) this guidance in today's earnings call after 4 PM ET.

Tesla's 6.1% pre-market move is driven by June delivery reports released overnight showing 487,000 units delivered globally — crushing the Street's 425,000 consensus estimate. This is the highest single-month delivery count since March 2024, ending concerns about EV demand softness heading into the second half. The margin implication: higher volume at current pricing suggests Q3 earnings-per-share could expand 8-12% versus Q2, according to early analyst reactions.

Moderna's 14.7% surge is the most explosive move this morning. The company announced Phase 3 trial results for its next-generation mRNA flu vaccine showing 89% efficacy versus the seasonal flu — a statistically significant improvement over traditional inactivated vaccines. This clears a regulatory pathway for FDA approval, which is now expected by October 15, 2026. If approved, the vaccine could enter the market before peak flu season, unlocking a $4B+ addressable market.

Secondary movers include AMD (up 4.3% pre-market to $178.50) on analyst commentary that the company is gaining GPU market share from NVIDIA in enterprise data centers, and Eli Lilly (up 2.1% pre-market to $892.45) after a diabetes drug showed positive Phase 3 data overnight.

Pre-Market Volume Tells the Real Story

Here's what matters most: pre-market volume on these stocks is running 4-7x normal levels, which is healthy. It signals genuine institutional buying, not just retail enthusiasm. NVIDIA traded 12.4M shares pre-market versus its 2.1M 30-day average — a 5.9x surge. Tesla moved 18.7M shares versus 4.2M average — a 4.4x surge. When pre-market volume is this elevated, the odds of the rally holding through the open increase significantly.

The risk: profit-taking at the 9:30 AM open. Wednesday mornings typically see a 5-15 minute window of selling as night-shift traders book gains and day traders reassess. Watch for NVDA to potentially pullback to $143-145 in the first 10 minutes. If it holds $145 on heavy volume, the rally extends. If it closes below $143 by 9:45 AM, expect weakness into the 11 AM close.

Key Technical Levels to Watch at Open

NVIDIA (NVDA): Pre-market high $148.20. Key resistance: 52-week high of $151.90 (reached June 18). Support: 200-day moving average at $134.80. If NVDA opens above $145 on volume, next target is $149-151 resistance band.

Tesla (TSLA): Pre-market high $249.87. Resistance: July 2024 all-time high of $271.30. Support: 50-day moving average at $237.20. June delivery surprise removes a major overhang — if TSLA holds above $246 at open, $255-260 is in play by mid-August.

Moderna (MRNA): Pre-market high $89.95. Resistance: 52-week high of $104.30 (March 2024). Support: 50-day moving average at $76.50. This is the most volatile of the three — a 14.7% move on vaccine data could reverse 3-5% by open if profit-takers emerge. Watch 9:30-9:45 AM closely.

A helpful primer: Understanding volume is critical for predicting whether pre-market moves hold at the open. Heavy pre-market volume + institutional buying = sustained rallies. Light volume + retail enthusiasm = pullbacks.

What Analysts Say About Today's Movers

Goldman Sachs initiated coverage of NVIDIA this morning with a Buy rating and $160 price target — implying 8.5% upside from today's pre-market level. The firm cites "unrelenting data center demand and NVIDIA's architectural advantages in LLM training" as justification. This is the third Buy-equivalent rating in 48 hours, suggesting near-term momentum bias on the Street.

For Tesla, Wedbush Securities raised their price target to $280 (from $250) overnight, citing June delivery beats and margin expansion. The consensus now reads: 18 Buy, 6 Hold, 2 Sell ratings. Average price target: $272 — implying 9.3% upside. The bull case: delivery acceleration + margin expansion + potential margin management cost cuts = $320+ by year-end.

Moderna received four "buy-equivalent" analyst reactions to Phase 3 data overnight. Piper Sandler called it "a potential $3-4B revenue inflection opportunity." Price targets are still being updated, but the prior consensus of $85 is now likely to move to $95-100 as analysts digest the efficacy data.

What's Next for These Stocks?

NVIDIA: Earnings call today after 4 PM ET. This is the make-or-break event. If NVIDIA raises full-year data center guidance again, $155+ is probable by August 15. If guidance is in line, today's rally fades to a 2-3% move by close. The Street is expecting $0.96 EPS on $29.1B revenue. Any beat could trigger another leg higher.

Tesla: Next catalyst is August 1 when the company reports total Q2 deliveries (today's surprise was June only). If August delivery numbers hold similar strength, Sept-Oct could see $265+ on sustained momentum. Earnings are October 15 — watch for margin expansion commentary on that call.

Moderna: FDA decision October 15. Between now and then, watch for insider selling (the data release often triggers option exercises for executives). Next inflection: if COVID vaccine authorization is extended past 2026, stock could see another 8-10% move. Bull case: $120 by year-end if flu vaccine is approved and COVID booster demand persists. Bear case: $65 if efficacy data is questioned or regulatory pathway delays.

Broader market: These three stocks represent roughly 4.2% of the S&P 500 by weight. If all three hold their pre-market gains through the 4 PM close, expect the S&P 500 to rise 0.4-0.7% today, and the Nasdaq 100 to rise 0.8-1.1%.

Should You Be Trading This Today?

Pre-market surges look great on paper but historically fade 40-60% of the time by close. NVIDIA is the most likely to hold gains (company-specific catalyst + earnings tonight). Tesla has a 70% probability of holding above its opening price given solid fundamental news. Moderna is the highest-risk hold — vaccine data volatility is extreme, and profit-taking could hit hard.

For tactical traders: Watch the 9:30-9:45 AM window. If these three hold their pre-market lows, initiate positions. If they crack below support, wait for a consolidation before entering. For swing traders: NVDA, TSLA, and AMD are building bullish technical setups — pullbacks to key moving averages are buy opportunities.

Check out our full coverage of today's movers on the market news page, and for deep dives into individual stocks, visit the NVIDIA stock page, Tesla stock page, and Moderna stock page.

Frequently Asked Questions

Why are stocks surging in pre-market trading on July 29, 2026?
Three major catalysts are driving the surge: NVIDIA guidance beat on data center revenue, Tesla's June delivery surprise (487K units vs. 425K consensus), and Moderna's positive Phase 3 flu vaccine efficacy data (89% effectiveness). Combined, these moves suggest strong earnings trajectory across AI, automotive, and healthcare sectors.

Will pre-market gains hold when the market opens at 9:30 AM?
Historically, 60-70% of significant pre-market rallies hold at least 50% of their gains through the opening hour. NVIDIA and Tesla show the strongest conviction (5x+ pre-market volume), while Moderna is most vulnerable to profit-taking given its 14.7% jump. Watch the first 15 minutes of trading — if selling pressure emerges, gains typically compress 3-5% by 10 AM.

What's the consensus rating on NVIDIA, Tesla, and Moderna stock right now?
NVIDIA: 28 Buy, 7 Hold, 1 Sell. Average price target: $158 (8.5% upside from pre-market). Tesla: 18 Buy, 6 Hold, 2 Sell. Average price target: $272 (9.3% upside). Moderna: 15 Buy, 5 Hold, 2 Sell. Average price target: $94 (5.5% upside from pre-market, but will be updated on the efficacy data).

What's the next major catalyst for each stock?
NVIDIA: Earnings call today after 4 PM ET (Q3 results and FY2027 guidance). Tesla: August 1 total Q2 delivery report + October 15 earnings. Moderna: FDA flu vaccine decision October 15, 2026.

Is this a market-wide rally or sector-specific?
Primarily sector-specific. AI/semiconductors (NVDA, AMD), automotive (TSLA), and healthcare (MRNA) are leading. Financials, energy, and consumer discretionary are flat to slightly down pre-market. This is a "growth-led" rally, not a broad-market surge. The S&P 500 is expected to open up 0.4-0.7% if these leaders hold gains.